Health & Fitness News
FDA: Testosterone Products Must Warn About Clot Risk
(NEW YORK) -- The U.S. Food and Drug Administration is calling for manufacturers to include a general warning in the drug labeling of all approved testosterone products, drawing attention to the risk of vein blood clots.
The potential for venous blood clots is already included on labels for products as a possible consequence for the condition polycythemia, or an abnormal increase in the number of red blood cells, the agency announced Thursday.
As a result of increased reports of polycythemia, the FDA is requiring a change to "ensure this risk is described consistently" in all approved products.
Such products are approved for use in men who lack or have low testosterone levels associated with medical conditions, including genetic problems and chemotherapy.
The FDA adds that officials are continuing an evaluation of the possible risk of stroke, heart attack, and death in patients taking such drugs in relation to blood clots in patients' arteries.
Copyright 2014 ABC News Radio
See other Health news:Can a Jolting Wearable-Fitness Tracker Get You to Work Out?
American Doctor in Liberia Tests Positive for Ebola
Boy Battling Cancer Turns Six with 'Close to 100,000' Birthday Cards
American Red Cross Issues Urgent Call for Blood Donations
Playing Hard to Get May Not Work for Women, Study Says